Webinar with Dr. David Seftel (MD/ HBS MBA) to stay informed on COVID-19 updates. In this webinar, Dr. Seftel will share with us what he knows and what you can do to best protect yourself and your family. A follow-up email with slides and recording links will be sent after the event, and the recording will be available to members when logged in under the Event Videos tab.
Date: Thursday, June 11
Time: 7:00 – 8:00 pm PST
Location: Virtual – Zoom Call Details will be sent to you after you register
Are you an HBS alum, yet not a member? To join, log in and click on the Membership tab or email Randi Curhan to become a member.
“I’ve listened to a lot of conference calls on the subject. Dr. Seftel is BY FAR the best. Thank you for continuing this!!”
– Lilian Shackelford Murray, MBA 1984
About David Seftel, MD
David Seftel, M.D., M.B.A. is CEO and Chief Medical Officer of Enable Biosciences, a multi-award winning early and accurate disease diagnosis company based in South San Francisco, CA. Since inception in 2015, Enable has been awarded 10 grants from agencies including the National Institutes of Health, the National Science Foundation and the Juvenile Diabetes Research Fund and won the HBS New Venture Competition for the region in 2016. Enable’s researchers have also been supported by the Gates Foundation at Stanford. Enable is currently developing an improved rapid COVID-19 test with its public health laboratory partners. Dr. Seftel also serves as an Immunology research panel reviewer for the National Institutes of Health. He is currently the Principal Investigator for two additional research projects sponsored by the NIH/National Institutes of Allergy and Infectious Disease dealing with the development of ultrasensitive and highly specific diagnostic tests for a variety of difficult-to-detect diseases like Lyme disease and pediatric allergies. A Harvard Business School graduate, he did his clinical training at Harvard’s Beth Israel-Deaconess Hospital, Penn State and Loyola University of Chicago and served as a Co-Investigator in the landmark Stanford-JDRF-Enable Biosciences Type 1 Diabetes Assay Performance study.
Organized by Shannon Lundgren HBS ’94